参考文献/References:
［1］ Tepe G， Laird J， Schneider P， et al. Drug- coatedballoon versus standard percutaneous transluminal angioplasty for the treatment of superfial femoral and popliteal peripheral artery disease： 12- month resultsfrom the IN. PACT SFA randomized trial［J］. Circulation，2015， 131：495- 502.
［2］ Varetto G，Gibello L，Boero M，et al. Angioplasty or bare metal stent versus drug- eluting endovascular treatment in femoropo- pliteal artery disease： a systematic review and meta- analysis［J］. J Cardiovasc Surg（Torino）， 2019， 60：546- 556
［3］ Meng FC， Chen PL， Lee CY， et al. Real- world comparison of drug- eluting and bare- metal stents in superfial femoral artery occlusive disease with Trans- Atlantic Intersoety Consensus B lesions： a 2- year， single- institute study［J］. Acta Cardiol Sin， 2018， 34：130- 136.
［4］ Speck U， Cremers B， Kelsch B， et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?［J］. Circ Cardiovasc Interv， 2012， 5：392-400.
［5］ Shanmugasundaram M， Murugapandian S， Truong HT， et al. Drug- coated balloon in peripheral artery disease［J］. Cardiovasc Revasc Med， 2019， 20：338- 343.
［6］ Tepe G， Micari A， Keirse K，et al. Drug- coated balloon treat-ment for femoropopliteal artery disease： the chronic total occlusion cohort in the IN. PACT global study［J］. JACC Cardiovasc Interv，2019， 12：484- 493
［7］ Roh JW，Ko YG，Ahn CM， et al. Risk factors for restenosis after drug- coated balloon angioplasty for complex femoropopliteal arterial occlusive disease［J］. Ann Vasc Surg， 2019， 55： 45- 54.
［8］ Iida O，Soga Y，Urasawa K， et al. Drug- coated balloon vs standard percutaneous transluminal angioplasty for the treatment of athero- sclerotic lesions in the superfial femoral and proximal- popliteal arteries： one- year results of the MDT- 2113 SFA Japan randomized trial［J］. J Endovasc Ther， 2018， 25：109- 117.
［9］ Rosenfield K， Jaff MR， White CJ， et al. LEVANT 2 investigators. Trial of a paclitaxel- coated balloon for femoropopliteal artery disease［J］. N Engl J Med， 2015， 373：145-153.
［10］ Schmidt A， Piorkowski M， Gorner H， et al. Drug- coated balloons for complex femoropopliteal lesions： 2- year results of a real- world registry［J］. JACC Cardiovasc Interv， 2016， 9：715- 724.
［11］ 刘 昆，辛世杰，张 健，等. 贫血与下肢动脉硬化闭塞症相关性研究［J］. 中国血管外科杂志（电子版）， 2012， 4：161- 162
［12］ Desormaisa I， Aboyans V， Bura A， et al. Anemia， an indepen-dent predictive factor for amputation and mortality in patients hospitalized for peripheral artery disease［J］. Eur J Vasc Endovasc Surg， 2014， 48：202- 207.
［13］ Vega de Ceniga M， Bravo E， Izagirre M， et al. Anaemia， iron and vitamin deficits in patients with peripheral arterial disease［J］. Eur J Vasc Endovasc Surg， 2011， 41：828- 830
［14］ Velescu A，Clara A， Cladellas M， et al. Anemia increases mortality after open or endovascular treatment in patients with critical limb ischemia： a retrospective analysis［J］. Eur J Vasc Endovasc Surg， 2016， 51：543- 549
［15］ 王海瑞，潘 涛，畅智慧，等. 股腘动脉闭塞支架植入术后支架内再狭窄危险因素——贫血［J］. 介入放射学杂志， 2016， 25：1007- 1010
［16］ 王 敏，班 博，张 梅，等. 2 型糖尿病患者贫血与微血管病变的相关研究进展［J］. 中国全科医学杂志， 2020， 23：1717- 1721
［17］ Ozturk C，Ozturk A. The relationship between bilirubin levels and atherosclerosis［J］． Angiology， 2015， 66：96.
［18］ 吴 磊，庞 燕，尹博文，等. 胆红素及糖化血红蛋白与老年症状性颅内动脉狭窄支架置入术后再狭窄的相关性［J］. 中国老年学杂志， 2019， 39：5177- 5179
［19］ 杨天贵，付 鹏，牛铁生. 血清总胆红素与支架内再狭窄的相关性研究［J］. 临床心血管病杂志， 2017， 33：646- 649.
［20］ Peterson S， Hasenbank M， Silvestro C， et al. IN. PACT TM AdmiralTM drug- coated balloon： durable， consistent and safe treatment for femoropopliteal peripheral artery disease［J］. Adv Drug Deliv Rev， 2017， 112：69- 77
［21］ 王逸增，张 韬，张小明，等. 药物涂层球囊在股腘动脉硬化性闭塞症中的疗效及预后相关因素［J］. 中国血管外科杂志（电子版）， 2019， 11：15- 19
相似文献/References:
[1]钱钧,姜宏,杨晓红.内膜下再通术在股腘动脉腔内成形术中的应用[J].介入放射学杂志,2011,(02):103.
QIAN Jun,JIANG Hong,YANG Xiao-hong..The application of subintimal recanalization in percutaneous transluminal angioplasty for chronic long-segment occlusion of femoropopliteal artery[J].journal interventional radiology,2011,(08):103.
[2]王海瑞,潘 涛,畅智慧,等.股腘动脉闭塞支架植入术后支架内再狭窄危险因素——贫血 [J].介入放射学杂志,2016,(11):1007.
WANG Hai- rui,PAN Tao,CHANG Zhi- hui,et al.Anemia： a risk factor of in- stent restenosis after stenting for femoropopliteal artery occlusion[J].journal interventional radiology,2016,(08):1007.
[3]项以力,张温凯,杨 镛.药物涂层球囊和无涂层球囊治疗股腘动脉缺血性疾病疗效及安全性meta分析 [J].介入放射学杂志,2017,(06):500.
XIANG Yili,ZHANG Wenkai,YANG Yong.Drug- coated balloon versus uncoated balloon angioplasty for femoropopliteal artery ischemic disease： a meta- analysis of curative effect and safety[J].journal interventional radiology,2017,(08):500.
[4]刘晓哲,王 兵,刘俊超,等.药物涂层球囊在股腘动脉支架内再狭窄治疗中的应用 [J].介入放射学杂志,2018,27(05):410.
LIU Xiaozhe,WANG Bing,LIU Junchao,et al.Application of drug- coated balloon in treating femoropopliteal in- stent restenosis[J].journal interventional radiology,2018,27(08):410.
[5]陈 英.生化指标与股腘动脉慢性完全闭塞病变支架内再狭窄相关性分析[J].介入放射学杂志,2020,29(07):664.
CHEN Ying..The correlation between biochemical indexes and in-stent restenosis of chronic total occlusion of femoropopliteal artery[J].journal interventional radiology,2020,29(08):664.